SCHEMBL4997066

SCHEMBL4997066

COc1cc(N/C=C2/C(=O)Nc3ccccc32)cc(OC)c1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.60
ALDH1A1 P00352 4/20 0.60
SMN1; SMN2 Q16637 4/20 0.60
CSNK1D P48730 3/20 0.60
CSNK1A1 P48729 3/20 0.60
CSNK1E P49674 2/20 0.60
LMNA P02545 2/20 0.60
MAPK1 P28482 2/20 0.60
RAB9A P51151 2/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
GMNN O75496 1/20 0.60
TP53 P04637 1/20 0.60
CYP1A2 P05177 1/20 0.60
CYP3A4 P08684 1/20 0.60
CYP2C9 P11712 1/20 0.60
HPGD P15428 1/20 0.60
CYP2C19 P33261 1/20 0.60
THPO P40225 1/20 0.60
BLM P54132 1/20 0.60
PMP22 Q01453 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4997078 1.00 MAPT (0.60) MAPTALDH1A1SMN1; SMN2CSNK1DCSNK1A1
SCHEMBL4994792 0.90 ALDH1A1 (0.60) MAPTALDH1A1SMN1; SMN2CSNK1DCSNK1A1
SCHEMBL11887935 0.90 ALDH1A1 (0.60) MAPTALDH1A1SMN1; SMN2CSNK1DCSNK1A1
SCHEMBL4994789 0.90 ALDH1A1 (0.60) MAPTALDH1A1SMN1; SMN2CSNK1DCSNK1A1
SCHEMBL4985173 0.88 MAPT (0.60) MAPTALDH1A1SMN1; SMN2CSNK1DCSNK1A1
SCHEMBL11887926 0.88 MAPT (0.60) MAPTALDH1A1SMN1; SMN2CSNK1DCSNK1A1
SCHEMBL4985182 0.88 MAPT (0.60) MAPTALDH1A1SMN1; SMN2CSNK1DCSNK1A1
SCHEMBL13621635 0.85 NPC1 (0.54) MAPTALDH1A1SMN1; SMN2CSNK1DCSNK1A1
SCHEMBL4997074 0.84 CDYL2 (0.59) MDM2RETTGM2IDO1
SCHEMBL4997080 0.84 CDYL2 (0.59) MDM2RETTGM2IDO1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7414054-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2008-08-19 US disclosed
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-08-31 US disclosed
US-7098236-B2 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-08-29 US disclosed
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-03-23 US disclosed
US-7015220-B2 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. (US) 2006-03-21 US disclosed
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2006-02-02 US disclosed
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2005-10-13 US disclosed
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ANDREWS STEVEN W (US) 2004-10-07 US disclosed
US-6765012-B2 FOR MODULATING TYROSINE KINASE SIGNAL TRANSDUCTION IN ORDER TO REGULATE, MODULATE AND/OR INHIBIT ABNORMAL CELL PROLIFERATION ALLERGAN, INC. 2004-07-20 US disclosed
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-12-04 US disclosed
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ALLERGAN, INC. 2003-10-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050228036-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MAPT 3370/4885ALDH1A1 1651/4885SMN1; SMN2 4396/4885
US-20030199478-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MAPT 3370/4885ALDH1A1 1651/4885SMN1; SMN2 4396/4885
US-20060194863-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MAPT 3370/4885ALDH1A1 1651/4885SMN1; SMN2 4396/4885
US-20060025413-A1 3-(arylamino)methylene-1,3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MAPT 3370/4885ALDH1A1 1651/4885SMN1; SMN2 4396/4885
US-20060063940-A1 3-(arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MAPT 3370/4885ALDH1A1 1651/4885SMN1; SMN2 4396/4885
US-20030225152-A1 3-(Arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MAPT 3370/4885ALDH1A1 1651/4885SMN1; SMN2 4396/4885
US-20040198720-A1 3-(Arylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors ERBB2, MKI67, CDK2 MAPT 3370/4885ALDH1A1 1651/4885SMN1; SMN2 4396/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.